Ototoxic ear drops are ear drops containing a medicine that can damage the inner ear, mainly the aminoglycoside antibiotics neomycin, framycetin and gentamicin. The concern arises when the eardrum is not intact: through a perforation or a grommet (tympanostomy tube), drops reach the middle ear, and aminoglycosides placed there harm the inner ear in animal studies.

Why it matters for tinnitus

A US label for a neomycin-containing ear suspension warns that neomycin can cause permanent sensorineural hearing loss by destroying the cochlea's hair cells, more so with prolonged use; it limits treatment to 10 consecutive days and rules the product out with a perforated eardrum. Damaged hair cells are central to the leading explanation of how tinnitus arises. In people, though, the documented harm from gentamicin drops has fallen mostly on balance.

What the evidence says

  • Animal studies. A 2004 systematic review of 61 animal papers found virtually all showed aminoglycosides to be ototoxic in the middle ear. Ofloxacin's label reports no drug-related cochlear changes in guinea pigs given its drops for a month.
  • Case reports and series. A 2004 review of published cases counted 54 people with balance damage from gentamicin drops, 24 also with cochlear damage, and 11 cochlear and 2 balance injuries from neomycin-based drops. In a Toronto series of 16 people with ototoxicity from gentamicin drops, all had balance damage and 1 a noticeable cochlear loss; inadvertent cases had all used the drops for over 7 days. A Zurich chart review of 134 patients assessed for possible antibiotic ototoxicity attributed profound hearing loss in both ears in 2 to excessive use of framycetin- and polymyxin-containing drops through a perforation.
  • Cohort. Among 134,598 US children on Medicaid with a perforation or tympanostomy tube, one prescription of neomycin drops was not linked to more sensorineural hearing loss than fluoroquinolone drops (adjusted hazard ratio 0.90); two were (1.45); three or more did not reach significance (1.30).
  • Systematic reviews of trials. A 2025 Cochrane review found eight trials comparing aminoglycoside with quinolone drops for chronic ear discharge. Quinolones may clear discharge better (very low certainty); harms were too poorly reported to compare the classes. A 2016 systematic review of nine trials concluded that quinolones are at least as effective, do not carry the same ototoxic risk, and should be considered first-line.
  • Guidelines. The US acute otitis externa guideline recommends a non-ototoxic preparation whenever a perforation is known or suspected, including a tympanostomy tube; ofloxacin drops are US-labelled for infected ears with a perforation or tympanostomy tube. ENT-UK's 2007 consensus, calling the evidence poor, limits aminoglycoside drops through a perforation or grommet to obvious infection and 2 weeks, with the reason explained and, where possible, a hearing test first.
  • Tinnitus. On tinnitus itself, the evidence is thin: 3 PubMed records match ear drops, ototoxicity and tinnitus. In a 2025 Cochrane review of antibiotic–steroid drops, one trial of 123 people found no difference in tinnitus against saline or no treatment (very low certainty). In ofloxacin's approval trials, tinnitus was recorded as treatment-related in 0.3% of 656 people with a non-intact eardrum.

What this means for you

  • If you have, or might have, a hole in your eardrum or a grommet, tell whoever prescribes or supplies ear drops; the US guideline for swimmer's ear asks clinicians to check.
  • Aminoglycoside drops through a perforation can be a deliberate choice for an infected ear. Ask the prescriber why, for how long, and whether a hearing test should come first, rather than stopping prescribed drops on your own.
  • Report new unsteadiness, dizziness, muffled hearing, or new or louder tinnitus to the prescriber promptly. Sudden hearing loss, over hours to a few days, needs same-day assessment. Severe vertigo or loss of balance that will not settle is an emergency: call your local emergency number or go to an emergency department.

How it connects